Citations

Clear

7 citation(s) found for "Sowell, SR".

Practice guideline update summary: Acute treatment of migraine in children and adolescents
Pringsheim, Tamara , Holler‐Managan, Yolanda, Potrebic, Sonja , Billinghurst, Lori , Gloss, David , Hershey, Andrew D. , Licking, Nicole, Sowell, Michael, Victorio, M. Cristina, Gersz, Elaine , Leininger, Emily, Zanitsch, Heather, Yonker, Marcy, Mack, Kenneth J. , Mack, Kenneth, Hershey, Andrew , Oskoui, Maryam , Pringsheim, Tamara

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 17, 2019 | Volume: 59 | Issue: 8 | Pages: 1158-1173

10.1111/head.13628 | PMID 31529481 Get It

Objective To provide evidence‐based recommendations for the acute symptomatic treatment of children and adolescents with migraine. Methods We performed a systematic review of the literature and rated risk of bias of included studies according to the American Academy of Neurology classification of evidence criteria. A multidisciplinary panel developed practice recommendations, integrating findings from the systematic review and following an Institute of Medicine‐compliant process to ensure transparency and patient engagement. Recommendations were supported by structured rationales, integrating evidence from the systematic review, related evidence, principles of care, and inferences from evidence. Results There is evidence to support the efficacy of the use of ibuprofen, acetaminophen (in children and adolescents), and triptans (mainly in adolescents) for the relief of migraine pain, although confidence in the evidence varies between agents. There is high confidence that adolescents receiving oral sumatriptan/naproxen and zolmitriptan nasal spray are more likely to be headache free at 2 hours than those receiving placebo. No acute treatments were effective for migraine‐related nausea or vomiting; some triptans were effective for migraine‐related phonophobia and photophobia. Recommendations Recommendations for the treatment of acute migraine in children and adolescents focus on the importance of early treatment, choosing the route of administration best suited to the characteristics of the individual migraine attack, and providing counselling on lifestyle factors that can exacerbate migraine, including trigger avoidance and medication overuse.
Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention
Pringsheim, Tamara , Billinghurst, Lori , Potrebic, Sonja , Gersz, Elaine , Gloss, David , Holler‐Managan, Yolanda, Leininger, Emily, Licking, Nicole, Mack, Kenneth J. , Powers, Scott W. , Sowell, Michael, Victorio, M. Cristina, Yonker, Marcy, Zanitsch, Heather, Hershey, Andrew D. , Mack, Kenneth, Hershey, Andrew , Oskoui, Maryam

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 17, 2019 | Volume: 59 | Issue: 8 | Pages: 1144-1157

10.1111/head.13625 | PMID 31529477 Get It

Objective To provide updated evidence‐based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population. Methods The authors systematically reviewed literature from January 2003 to August 2017 and developed practice recommendations using the American Academy of Neurology 2011 process, as amended. Results Fifteen class I‐III studies on migraine prevention in children in adolescents met inclusion criteria. There is insufficient evidence to determine if children and adolescents receiving divalproex, onabotulinumtoxinA, amitriptyline, nimodipine and flunarizine are more or less likely than those receiving placebo to have a reduction in headache frequency. Children with migraine receiving propranolol are possibly more likely than those receiving placebo to have an at least 50% reduction in headache frequency. Children and adolescents receiving topiramate and cinnarizine are probably more likely than those receiving placebo to have a decrease in headache frequency. Children with migraine receiving amitriptyline plus cognitive behavioral therapy are more likely than those receiving amitriptyline plus headache education to have a reduction in headache frequency. Recommendations The majority of randomized controlled trials studying the efficacy of preventive medications for pediatric migraine fail to demonstrate superiority to placebo. Recommendations for the prevention of migraine in children include counseling on lifestyle and behavioral factors that influence headache frequency, and assessment and management of comorbid disorders associated with headache persistence. Clinicians should engage in shared decision making with patients and caregivers regarding the use of preventive treatments for migraine, including discussion of the limitations in the evidence to support pharmacologic treatments.
The failing Fontan: what’s NEXT…?
Sowell, SR, Willis, BC, Je, Lane, Pierce, C.N., Fa, Arabia, Pophal, SG, Nigro, JJ, Sanders, Don B. , Park, Sung Sup , Derby, Christopher D. , Pophal, Stephen

Mayo Clinic

Perfusion | July 11, 2013 | Volume: 29 | Issue: 1 | Pages: 89-93

10.1177/0267659113495913 | PMID 23842614 Get It

The Fontan procedure represents the final stage of the transition to single ventricle physiology. Conversion of very complex congenital heart anatomy, such as hypoplastic left heart syndrome, double-outlet right ventricle or double-inlet left ventricle, to a single ventricle has grown in popularity as morbidity and mortality have improved. As these patients grow, survivors are at risk for impaired ventricular dysfunction, plastic bronchitis, protein-losing enteropathy and late failure. Late failing Fontan patients represent a particularly vexing scenario for clinicians, as the only durable treatment option is cardiac transplantation. However, in the short-term, some of these patients require support beyond medical management, with mechanical circulatory support via extracorporeal life support or a ventricular assist device. We report the successful bridge of an adolescent female post-Fontan conversion with late severe cardiac failure. The patient was initially resuscitated with extracorporeal life support, transitioned to a single Berlin Heart EXCOR® ventricular assist device and, subsequently, underwent successful cardiac transplantation.
A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: Replication in elderly and young populations
Roussotte, Florence F. , Jahanshad, Neda , Hibar, Derrek P., Sowell, Elizabeth R. , Kohannim, Omid , Barysheva, Marina, Hansell, Narelle K. , McMahon, Katie L. , Zubicaray, Greig I. de , Montgomery, Grant W. , Martin, Nicholas G. , Wright, Margaret J. , Weiner, Michael W. , Thompson, Paul M. , ADNI, the, Toga, Arthur W. , Jack, Clifford R. , ADNI, the, de Zubicaray, Greig I , Hansell, Narelle K , Martin, Nicholas G , Wright, Margaret J , Thompson, Paul M

Mayo Clinic

Human Brain Mapping | February 21, 2013 | Volume: 35 | Issue: 4 | Pages: 1226-1236

10.1002/hbm.22247 | PMID 23427138 Get It

Delta opioid receptors are implicated in a variety of psychiatric and neurological disorders. These receptors play a key role in the reinforcing properties of drugs of abuse, and polymorphisms in OPRD1 (the gene encoding delta opioid receptors) are associated with drug addiction. Delta opioid receptors are also involved in protecting neurons against hypoxic and ischemic stress. Here, we first examined a large sample of 738 elderly participants with neuroimaging and genetic data from the Alzheimer's Disease Neuroimaging Initiative. We hypothesized that common variants in OPRD1 would be associated with differences in brain structure, particularly in regions relevant to addictive and neurodegenerative disorders. One very common variant (rs678849) predicted differences in regional brain volumes. We replicated the association of this single‐nucleotide polymorphism with regional tissue volumes in a large sample of young participants in the Queensland Twin Imaging study. Although the same allele was associated with reduced volumes in both cohorts, the brain regions affected differed between the two samples. In healthy elderly, exploratory analyses suggested that the genotype associated with reduced brain volumes in both cohorts may also predict cerebrospinal fluid levels of neurodegenerative biomarkers, but this requires confirmation. If opiate receptor genetic variants are related to individual differences in brain structure, genotyping of these variants may be helpful when designing clinical trials targeting delta opioid receptors to treat neurological disorders. Hum Brain Mapp 35:1226–1236, 2014 . © 2013 Wiley Periodicals, Inc.
P2–171: Clinical predictors of progression to Alzheimer's disease in amnestic mild cognitive impairment
Fleisher, Adam , Sowell, B. Brooke, Taylor, Curtis, Gamst, Anthony, Petersen, Ronald C. , Thal, Leon J.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_10 | Pages: No page available

10.1016/j.jalz.2006.05.1009 Get It